Understanding Biological Indicator Grow-Out Times—Part II - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Understanding Biological Indicator Grow-Out Times—Part II
In Part II of a series, the authors report on the range and distribution of grow-out times for biological indicators exposed to sublethal sterilization processes.


Pharmaceutical Technology
Volume 37, Issue 6, pp. 52-59

References

1. J.R. Gillis et al, Pharm. Technol. online http://www.pharmtech.com/pharmtech/Peer-Reviewed+Research/Understanding-Biological-Indicator-Grow-Out-Times/ArticleStandard/Article/detail/651903/, Jan. 2, 2010, accessed May 6, 2013.

2. FDA Guide for Validation of Biological Indicator Incubation Time (1986).

3. USP 32–NF 27 General Chapter <1211>, "Sterilization and Sterility Assurance of Compendial Articles," 720–723.

4. ISO 11138–1: 2006, Sterilization of health care products—Biological indicators—Part 1: General requirements, (ISO, Geneva, 2006).

5. ISO 14161: 2009, Sterilization of health care products—Biological indicators—Guidance for the selection, use and interpretation of results (ISO, Geneva, 2006).

6. ISO 18472: 2006, Sterilization of health care products—Biological and chemical indicators—Test equipment (ISO, Geneva, 2006).

7. H.O. Halverson and N.R. Ziegler, J Bacteriol. 25 101-121 (1933).

8. A.D. Russell, The Destruction of Bacterial Spores (Academic Press, London, 1982).

9. A. Hurst and G.W. Gould, The Bacterial Spore 2 (Academic Press, London, 1983).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
28%
Oversee medical treatment of patients in the US.
9%
Provide treatment for patients globally.
9%
All of the above.
41%
No government involvement in patient treatment or drug development.
13%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: Pharmaceutical Technology,
Click here